Celldex Therapeutics, Inc.
NASDAQ:CLDXBiotechnology
+$0.16 today
- Market cap
- $2.16B
- Beta
- 0.93
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$4.26
Volume 0.68M
Average 0.94M
CLDX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Celldex Therapeutics, Inc.NASDAQ: CLDX
Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Free cash flow grows, but more slowly than its trailing trend
Q3 FY2026 free cash flow of $66.7M (cash outflow) rose 35.9% year over year, behind the +42.8% change in trailing-twelve-month free cash flow. Sequentially, it rose 10.1% from the prior quarter. Over 3 fiscal years it compounded at +26.5% a year.
Context
- Free cash flow amounted to 14243.9% of revenue in FY2025, up 11969.0 pp from a year earlier.
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +35.9% toward the trailing-twelve-month pace of +42.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (213.66M) USD
- Year-over-year change
- -33.8%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (213.66M) | -33.8% |
| FY2024 | 2024-12-31 | (159.7M) | -46.4% |
| FY2023 | 2023-12-31 | (109.11M) | -3.4% |
| FY2022 | 2022-12-31 | (105.56M) | -69.8% |
| FY2021 | 2021-12-31 | (62.16M) | — |
Free Cash Flow vs competitors
How CLDX compares with its peers on the latest reported figures
- CLDX's LTM Sep 2026 free cash flow of $259.45M is the 3rd largest of the 10 companies compared; the peer median is $71.69M.
- Its year-over-year change of +42.8% is the 3rd highest of 8, against a peer median of +24.3%.
- Free cash flow amounts to 231652.7% of revenue for CLDX, versus a peer median of 70.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $475M | +38.9% | — | 406.0% | |
| LTM Aug 2026 | $369.81M | +253.2% | +15.3% | 52.7% | |
| LTM Sep 2026 | $259.45M | +42.8% | +26.5% | 231652.7% | |
| LTM Sep 2026 | $238.7M | +24.3% | +90.7% | — | |
| LTM Jun 2026 | $208.29M | +47.9% | +94.1% | 198.4% | |
| LTM Mar 2026 | $87.53M | -40.2% | -11.4% | 70.7% | |
| LTM Mar 2026 | $71.69M | -1.0% | -2.9% | 45.6% | |
| LTM Mar 2026 | $53.29M | +20.5% | +12.7% | — | |
| LTM Jun 2024 | $28.47M | — | -31.7% | 3489.8% | |
| LTM Dec 2025 | $0 | — | — | 0.0% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CLDX) | $71.69M | +24.3% | +12.7% | 70.7% | |
Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.51M) | (112.33M) | (141.43M) | (157.86M) | (258.76M) |
| Depreciation & Amortization | 3.07M | 2.9M | 3.01M | 3.18M | 3.38M |
| Deferred Income Tax | (227K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.95M | 0 | 23.89M | 34.24M | 36.22M |
| Change in Working Capital | (1.05M) | (3.9M) | 13.46M | (21.6M) | 14.06M |
| Accounts Receivables | 1.57M | (175K) | (2.28M) | 1.93M | (1.32M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.65M | 3.12M | 9.38M | 11.63M | 11.03M |
| Other Working Capital | (6.28M) | (6.85M) | 6.36M | (35.16M) | 4.34M |
| Other Non-Cash Items | (1.14M) | 9.6M | (6.22M) | (15.73M) | (5.84M) |
| Operating Cash Flow | (60.91M) | (103.73M) | (107.29M) | (157.78M) | (210.95M) |
| Capital Expenditures | (1.25M) | (1.83M) | (1.82M) | (1.92M) | (2.71M) |
| Acquisitions (Net) | 27K | 69K | 0 | 0 | 0 |
| Purchases of Investments | (389.88M) | (188.97M) | (424.56M) | (789.92M) | (384.5M) |
| Sales of Investments | 174.95M | 280.67M | 320.6M | 501.71M | 596.29M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (216.16M) | 89.94M | (105.78M) | (290.13M) | 209.07M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 269.89M | 4.08M | 216.22M | 432.3M | 2.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.48M | 0 | 2.24M | 9.15M | 0 |
| Financing Cash Flow | 272.37M | 4.08M | 218.46M | 441.45M | 2.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.69M) | (9.71M) | 5.39M | (6.46M) | 515K |
| Free Cash Flow | (62.16M) | (105.56M) | (109.11M) | (159.7M) | (213.66M) |
Celldex Therapeutics, Inc.
NASDAQ:CLDX
Intrinsic Alpha fair value
Locked
Current Price
$27.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.